دواعي استعمال تارسيفا 100مجم 30 قرص

Erlotinib 100 mg film-coated tablets, pack of 30 (Roche, distributed by Multipharma in Egypt).

• Metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations: first-line, maintenance, or after progression following at least one prior chemotherapy regimen.الفئة: AdultsDailyMed (US National Library of Medicine)
• First-line treatment of locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.الفئة: AdultsDailyMed (US National Library of Medicine)

• Most common (>= 20%): rash, diarrhoea, anorexia, fatigue, dyspnoea, cough, nausea and vomiting.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• None (US label).نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• Interstitial lung disease (1.1%): withhold for new or progressive unexplained pulmonary symptoms; discontinue if ILD is diagnosed.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• Renal failure and hepatotoxicity (including hepatic failure and hepatorenal syndrome): monitor renal function, electrolytes and liver tests; withhold or discontinue for severe toxicity.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• Gastrointestinal perforation, bullous/exfoliative skin disorders and corneal perforation or severe ulceration: discontinue.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• Increased risk of cerebrovascular accident and microangiopathic haemolytic anaemia in pancreatic cancer; haemorrhage with warfarin (monitor INR).نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• Embryo-fetal toxicity: females of reproductive potential should use effective contraception during treatment and for one month after the last dose.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir, voriconazole, grapefruit) or combined CYP3A4/CYP1A2 inhibitors (e.g. ciprofloxacin)Increase erlotinib exposure; avoid, or reduce the erlotinib dose if co-administration is unavoidable.DailyMed (US National Library of Medicine)
• CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, phenobarbital, St John's wort)Decrease erlotinib exposure; increase the erlotinib dose if co-administration is unavoidable.DailyMed (US National Library of Medicine)
• Cigarette smoking (CYP1A2 induction)Decreases erlotinib exposure; avoid smoking.DailyMed (US National Library of Medicine)
• Warfarin / coumarin anticoagulantsINR elevations and bleeding events reported; monitor INR regularly.DailyMed (US National Library of Medicine)

• Can cause fetal harm based on animal data and mechanism; embryo-fetal lethality and abortion in rabbits at about 3 times human exposure. Advise pregnant women of the risk.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
• No data on presence in human milk; advise not to breastfeed during treatment and for 2 weeks after the final dose.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• Periodic liver function tests; renal function and electrolytes (especially if at risk of dehydration); INR in patients on warfarin or other coumarins.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)

• Reversibly inhibits EGFR (HER1) tyrosine kinase activity.